Cite
HARVARD Citation
Cochrane, T. et al. (2022). Impact of venetoclax monotherapy on the quality of life of patients with relapsed or refractory chronic lymphocytic leukemia: results from the phase 3b VENICE II trial. Leukemia & lymphoma. 63 (2), pp. 304-314. [Online].